Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01926587 · ClinicalTrials.gov registry record · Phase 1
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase 1 study, sponsored by Traws Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT01926587 is a Phase 1 study that has completed, run by Traws Pharma. The registered enrollment target is 45 participants.
The verdict
NCT01926587, a Phase 1 study, has completed, sponsored by Traws Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study, is a Phase I/II clinical trial in three parts: Phase I Dose Escalation, Phase II, Part 1 RPTD Cohort, and Phase II, Part 2 Expansion. The first two parts have been completed. The Phase II, Part 2 Expansion will assess if treatment with rigosertib in combination with azacitidine, has measurable effects in patients with myelodysplastic syndrome (MDS). Safety of patients is an objective throughout all parts of the study.
Interventions
- DRUG Azacitidine
- DRUG oral rigosertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2013-08 |
| Est. Completion | 2021-02-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01926587
The ClinicalTrials.gov registry entry for NCT01926587 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Traws Pharma, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT01926587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01926587 about?
NCT01926587 is a clinical study titled "Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine". This study, is a Phase I/II clinical trial in three parts: Phase I Dose Escalation, Phase II, Part 1 RPTD Cohort, and Phase II, Part 2 Expansion. The first two parts have been completed. The Phase II, Part 2 Expansion will assess if treatment with rigosertib in combination with azacitidine, has meas...
What is the current status of trial NCT01926587?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2013-08. Estimated completion is 2021-02-16.
What interventions are being tested in trial NCT01926587?
The interventions under investigation include: Azacitidine (DRUG), oral rigosertib (DRUG).
Who is sponsoring clinical trial NCT01926587?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.